The MEA biologics and biosimilar market is expected to enjoy a valuation of US$ 512.6 Million in the year 2023, and further expand at a CAGR of 5.5% to reach a valuation of ~US$ 875.6 Million by the year 2033. According to a recent study by Future Market Insights, adalimumab in the drug segment is leading the market with a share of about 36.7% in the year 2022, within the MEA market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 485.9 Million |
| Market Value 2033 | US$ 875.6 Million |
| CAGR 2023 to 2033 | 5.5% |
| Market Share of Top 5 Countries | 87.2% |
| Key Market Players | AbbVie Inc., Eisai Co Ltd, Zydus Cadila(Cadila Healthcare), Amneal Pharmaceuticals, Inc., Pfizer Inc., Celltrion, Inc., Coherus BioSciences, Inc., F. Hoffmann–La Roche Ltd (Genentech, Inc.), Alexion(AstraZeneca), Johnson & Johnson, Amgen, and Hikma pharmaceuticals plc. |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for MEA biologics and biosimilar market was approximately 3.1% of the overall ~US$ 15.4 Billion global biologics and biosimilar market in 2021.
The most common cancers are breast cancer, lung and bronchus, colon and rectum, prostate, stomach, liver, cervix uteri, oesophagus, thyroid, and bladder.
to improve cancer patient care and ensure sure they have access to more effective, convenient, and affordable treatment options. MEA's expansion in oncology innovation is being fuelled by a flurry of new, oncology–focused biotech businesses and increased cancer research.
due to the rising incidence of numerous cancers, the market for biosimilar drugs is anticipated to expand in this region.
Manufacturers of biologics are adopting various strategies to respond to potential entrants in biosimilars.
Pharmaceutical manufacturers are concentrating on ways to broaden and improve formulations, dosing, expression systems, and delivery mechanisms.
For MabThera, for instance, Roche created a novel subcutaneous formulation that reduces treatment time from 2.5 hours to 5 minutes. This can enhance patient adherence and healthcare results.
To remain competitive and ensure a robust product pipeline, leading biopharmaceutical companies are continuing to focus on the development of innovative drugs associated with regular treatments and technologically advanced healthcare solutions to increase the adoption rate.
Over the next ten years, originator biologicals' patents and other intellectual property rights will expire, thus creating opportunities for biosimilars to enter the market and raising industry competition.
Governments using biosimilars as a less expensive alternative to cut healthcare costs is fueling demand. The value of the industry is also rising due to government initiatives, strategic partnerships, and an increase in the incidence of new diseases.
The market share of biosimilars is also growing as a result of deeper penetration into emerging markets in MEA countries.
New product approvals are expected to drive the market and provide prospects for manufacturers to present a diverse and innovative product portfolio.
There are several clinical trials ongoing for the development of biosimilars that have proved to be a better alternative to biologics. For instance, manufacturers are focused on the development of trastuzumab and rituximab biosimilars; some of these are approved, and others are still in the development stage.
Thus, the switch to biosimilars has the potential to have a significant impact. Moreover, developing nations require biosimilar drugs, as compounding pharmacies are extremely rare in these countries, which creates a huge market for manufacturers of biosimilars
Thus, owing to the forenamed factors, the MEA biologics and biosimilar market is expected to grow at a CAGR of 5.5% during the forecast period from 2023 to 2033.
Ustekinumab surpassed other medications in terms of annual increases in medical inflation-adjusted prices. Innovative strategies, such as the creation of biosimilars to improve patient access to care, are essential for reducing cost growth above inflation.
Global industry leaders are developing extended indications for already licensed biologics. The strategic approach involves the extension of the indication by conducting additional clinical investigations on the licensed biologics candidate.
The most advanced portfolios of biologics and biosimilars are held by early market leaders including AbbVie, Eisa Co Ltd., and Janssen Pharmaceuticals, a division of Johnson & Johnson.
According to WHO (2022), Non-communicable disease mortality is dramatically increasing in Middle Eastern and African (MEA) nations. 74% of all deaths in MEA are caused due to non-communicable diseases, which cause more than 38 million deaths annually worldwide.
For non-communicable diseases with a high prevalence, like cancer, diabetes, and rheumatoid arthritis, biosimilar drugs are readily available across major therapeutic categories.
The global picture of biologic therapy access is still uneven across high–income and low-income nations, and it reflects other inequalities in infrastructure, infrastructure, and economy.
The reinvestment of savings related to lower costs on biosimilar medicines compared to innovator biologic drugs has resulted in improved and more equitable access to biologic therapies and to healthcare in general in various countries.
This can be considered an opportunistic factor for the manufacturers operating within the MEA biologics and biosimilar market.
Principal Consultant
The number of manufacturers that can successfully launch biosimilar pharmaceuticals on the market in various nations throughout the world is constrained by prolonged, expensive, ineffective, and diverse regulatory approval procedures.
Despite the approval of the WHO Similar Biotherapeutic Product (SBP) guideline in 2009, several countries have failed to actively accept and execute the WHO's recommendations for biosimilar medicines.
There are a variety of off-patent biologic drugs available in low- and middle-income countries (LMICs), some of which are quality-assured biosimilars by WHO guidelines, but others are not, creating complexity. The level of regulatory maturity varies substantially throughout the Middle East and Africa (MEA) region.
Thus, stringent government regulations can be a major hindrance that can restrict the market growth in MEA.
Biologic therapeutics are not always accessible to eligible patients, due to high co–payments, limited or non–existent utilization, and/or lack of reimbursement for the original biologic product.
A significant portion of the population in the United Arab Emirates (UAE) is covered by private payers. The complexity of providing affordable access is increased by the growth of private payers and health insurance programs.
Many physicians prefer to be loyal to the original pharmaceutical manufacturers, whose products they are familiar with and have used for years. The utilization of biosimilar medications remains limited even when a payer adds one to their regimen.
Therefore, the lack of reimbursement for the costlier biologics can limit the use of biologics in the MEA region.
The mentioned factors collectively propose an adverse effect on the developmental growth of the MEA biologics and biosimilar market.
The KSA accounted for around 34.1% market share in the MEA biologics and biosimilar market in 2022, and a similar trend is expected over the forecast period.
KSA is evolving towards a more favorable environment for significant uptake of biosimilars, taking into account growing government emphasis on enhancing patient access to medications, financial restrictions, and the presence of a regulatory framework. The availability of medications in the KSA biologics and biosimilar market has increased as a result of expectations that KSA will be the most lucrative nation in the biologics and biosimilar industry.
In 2022, UAE held the highest market share of about 19.3% 2022 in the UAE biologics and biosimilar market.
There has been increased investment by local and regional companies in the biosimilar space considering the untapped opportunity UAE in partnership with Biocad, Sedico. Anticancer biologics are also used in the region because cancer is now the second most frequent cause of death, after heart disease.
Kuwait held approximately 14.8% market share in the MEA biologics and biosimilar market in 2022. Because of the expanding population and rising medication demand, Kuwait is developing quickly. Nowadays, the perspectives of stakeholders, physicians, and pharmacists have changed. Their strong conviction in generics and biosimilars is rising as a result of their low cost and convenient administration manner.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The adalimumab segment in the drug category of the MEA biologics and biosimilar market accounts for a market share of about 36.7% in the MEA market in 2022.
Patients with moderate to severe active psoriatic arthritis benefit from adalimumab treatment, which lessens joint and skin symptoms of the condition as well as disability brought on by joint destruction. Adalimumab shows a quick onset of effect and continued efficacy over the course of treatment.
The TNF Alfa Inhibitors in the drug class segment have become more and more popular, accounting for the greatest proportion of 29.1% in 2022. TNF-alpha inhibitors can be helpful for a variety of inflammatory conditions, including psoriasis, spondyloarthritis, rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). TNF-alpha inhibitors offer a targeted approach in contrast to the non-specific immunosuppressive medications that are frequently utilised to treat the bulk of inflammatory diseases.
The subcutaneous dosage form segment accounts for around 52.2% of the global market share in 2022. Individuals or healthcare professionals utilizing a variety of different drug delivery systems can administer therapeutics subcutaneously. SC administration lowers the fixed expenses associated with running a medical facility because it allows patients to self-administer in outpatient or home settings. The anatomical infusion location is flexible with SC administration, and alternatives include the stomach, thighs, and backs of the arms.
Arthritis in the indication segment accounts for a global market share of around 28.2% in 2022. A person's total function and mobility may be impacted by arthritis, which may lead to activity and other limits. According to recent studies, the likelihood of developing arthritis increases with age, body mass index, physical inactivity, and declining physical and mental health. Adults who are unable to work, incapacitated, or have fair or poor self–rated health have the highest rates of arthritis.
With 85.1% of the market share, the institutional sales segment in the distribution channel category dominated the MEA biologics and biosimilar market in 2022. Institutional sales leaders from the biotech, pharmaceutical, and medical device sectors collaborate with GPOs, ACOs, and IDNs to launch successful products across the country, thus propelling segment value.
The leading players invest in several product launches, expansions, partnerships, mergers, and acquisitions to increase their market share globally and enhance their business strategies. The major companies in the MEA biologics and biosimilar market have embraced these as their top–tier primary promotional methods.
Hikma Pharmaceuticals announced in July 2022 that it has signed a marketing agreement for Celltrion's YuflymaTM drug.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the MEA biologics and biosimilar market space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value & Volume (Units) |
| Key Region Covered | Middle East & Africa |
| Key Countries Covered | UAE, Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, KSA, Iran, and Palestine |
| Key Market Segments Covered | Drug, Drug Class, Dosage Form, Indication, Distribution Channel and Country |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The overall market value is estimated to be around US$ 875.6 million in 2023.
AbbVie, Eisai, and Zydus Cadila are some top service providers in the MEA market.
KSA leads and accounted for 34.1% of the total sales in MEA in 2022.
Improving patient access to healthcare and reducing cost growth above inflation.
The adalimumab drug segment accounted for 36.7% of the regional market in 2022.
1. Executive Summary | MEA Biologics and Biosimilar Market
1.1. MEA Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Drug Innovation / Development Trends
4. Key Success Factors
4.1. Regulatory Scenario
4.2. Pipeline Assessment
4.3. Key Marketing & Promotional Strategies Adopted by Companies
4.4. PESTLE Analysis
4.5. Porter’s Analysis
4.6. Value Chain Analysis
5. Market Background
5.1. Macro–Economic Factors
5.1.1. MEA GDP Growth Outlook
5.1.2. MEA Healthcare Expenditure
5.1.3. Global Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase in Research and Development Funding and Grants
5.2.2. High Demand for Biologics
5.2.3. Surge in Research Collaborations for the Development of Drugs
5.2.4. New Product Launch
5.2.5. Regulatory Approvals
5.2.6. Cost of Drugs
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Drug
6.1.2. Revenue By Drug Class
6.1.3. Revenue By Dosage Form
6.1.4. Revenue By Indication
6.1.5. Revenue By Distribution Channel
6.1.6. Revenue By Country
6.2. 2021 Market Scenario
7. MEA Market Demand Volume (Units) Analysis 2017 to 2022 and Forecast 2023 to 2033
7.1. Historical Market Volume (Units) Analysis, 2017 to 2022
7.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
7.2.1. Y–o–Y Growth Trend Analysis
8. MEA Market - Pricing Analysis
8.1. MEA Average Pricing Analysis Benchmark
8.2. Pricing Assumptions
9. MEA Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033
9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
9.2. Current Market Value (US$ Million) Forecast 2023 to 2033
9.2.1. Y–o–Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Drug, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis By Drug, 2023 to 2033
10.3.1. Adalimumab
10.3.2. Bevacizumab
10.3.3. Trastuzumab
10.3.4. Ustekinumab
10.3.5. Golimumab
10.3.6. Eculizumab
10.3.7. Rituximab
10.4. Market Attractiveness Analysis By Drug
11. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis By Drug Class, 2023 to 2033
11.3.1. Antirheumatics
11.3.2. TNF Alfa Inhibitors
11.3.3. VEGF/VEGFR Inhibitors
11.3.4. HER2 Inhibitors
11.3.5. Selective Immunosuppressants
11.3.6. Interleukin Inhibitors
11.4. Market Attractiveness Analysis By Drug Class
12. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Dosage Form
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis By Dosage Form, 2023 to 2033
12.3.1. Subcutaneous
12.3.2. Intravenous
12.4. Market Attractiveness Analysis By Dosage Form
13. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis By Indication, 2023 to 2033
13.3.1. Cancer
13.3.2. Arthritis
13.3.2.1. Rheumatoid
13.3.2.2. Psoriatic
13.3.2.3. Others
13.3.3. Skin Disorders
13.3.3.1. Plaque-Type Psoriasis
13.3.3.2. Hidradenitis Suppurativa
13.3.4. Inflammatory Bowel Disease (IBD)
13.3.4.1. Crohn's Disease
13.3.4.2. Ulcerative Colitis
13.3.5. Rare Disease
13.3.6. Others
13.4. Market Attractiveness Analysis By Indication
14. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis By Distribution Channel, 2023 to 2033
14.3.1. Institutional Sales
14.3.1.1. Hospitals
14.3.1.2. Specialty Clinics
14.3.1.3. Cancer Research Centers
14.3.2. Retail Sales
14.3.2.1. Retail Pharmacies
14.3.2.2. Mail Order Pharmacies/Online Sales
14.4. Market Attractiveness Analysis By Distribution Channel
15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis, By Country, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis By Country, 2023 to 2033
15.3.1. UAE
15.3.2. Kuwait
15.3.3. Qatar
15.3.4. Bahrain
15.3.5. Oman
15.3.6. Lebanon
15.3.7. Jordan
15.3.8. Palestine
15.3.9. Iraq
15.3.10. KSA
15.3.11. Iran
15.4. Market Attractiveness Analysis By Country
16. UAE Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
16.3.1. By Drug
16.3.2. By Drug Class
16.3.3. By Dosage Form
16.3.4. By Indication
16.3.5. By Distribution Channel
16.4. Drivers and Restraints - Impact Analysis
16.5. Market Attractiveness Analysis By UAE
17. Kuwait Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
17.3.1. By Drug
17.3.2. By Drug Class
17.3.3. By Dosage Form
17.3.4. By Indication
17.3.5. By Distribution Channel
17.4. Drivers and Restraints - Impact Analysis
17.5. Market Attractiveness Analysis By Kuwait
18. Qatar Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
18.3.1. By Drug
18.3.2. By Drug Class
18.3.3. By Dosage Form
18.3.4. By Indication
18.3.5. By Distribution Channel
18.4. Drivers and Restraints - Impact Analysis
18.5. Market Attractiveness Analysis By Qatar
19. Bahrain Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
19.3.1. By Drug
19.3.2. By Drug Class
19.3.3. By Dosage Form
19.3.4. By Indication
19.3.5. By Distribution Channel
19.4. Drivers and Restraints - Impact Analysis
19.5. Market Attractiveness Analysis By Bahrain
20. Oman Market Analysis 2017 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
20.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
20.3.1. By Drug
20.3.2. By Drug Class
20.3.3. By Dosage Form
20.3.4. By Indication
20.3.5. By Distribution Channel
20.4. Drivers and Restraints - Impact Analysis
20.5. Market Attractiveness Analysis By Oman
21. Lebanon Market Analysis 2017 to 2022 Forecast 2023 to 2033
21.1. Introduction
21.2. Pricing Analysis
21.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
21.4. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
21.4.1. By Drug
21.4.2. By Drug Class
21.4.3. By Dosage Form
21.4.4. By Indication
21.4.5. By Distribution Channel
21.5. Drivers and Restraints - Impact Analysis
21.6. Market Attractiveness Analysis By Lebanon
22. Jordan Market Analysis 2017 to 2022 and Forecast 2023 to 2033
22.1. Introduction
22.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
22.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
22.3.1. By Drug
22.3.2. By Drug Class
22.3.3. By Dosage Form
22.3.4. By Indication
22.3.5. By Distribution Channel
22.4. Drivers and Restraints - Impact Analysis
22.5. Market Attractiveness Analysis By Jordan
23. Palestine Market Analysis 2017 to 2022 and Forecast 2023 to 2033
23.1. Introduction
23.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
23.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
23.3.1. By Drug
23.3.2. By Drug Class
23.3.3. By Dosage Form
23.3.4. By Indication
23.3.5. By Distribution Channel
23.4. Drivers and Restraints - Impact Analysis
23.5. Market Attractiveness Analysis By Palestine
24. Iraq Market Analysis 2017 to 2022 and Forecast 2023 to 2033
24.1. Introduction
24.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
24.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
24.3.1. By Drug
24.3.2. By Drug Class
24.3.3. By Dosage Form
24.3.4. By Indication
24.3.5. By Distribution Channel
24.4. Drivers and Restraints - Impact Analysis
24.5. Market Attractiveness Analysis By Iraq
25. KSA Market Analysis 2017 to 2022 and Forecast 2023 to 2033
25.1. Introduction
25.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
25.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
25.3.1. By Drug
25.3.2. By Drug Class
25.3.3. By Dosage Form
25.3.4. By Indication
25.3.5. By Distribution Channel
25.4. Drivers and Restraints - Impact Analysis
25.5. Market Attractiveness Analysis By KSA
26. Iran Market Analysis 2017 to 2022 and Forecast 2023 to 2033
26.1. Introduction
26.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
26.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
26.3.1. By Drug
26.3.2. By Drug Class
26.3.3. By Dosage Form
26.3.4. By Indication
26.3.5. By Distribution Channel
26.4. Drivers and Restraints - Impact Analysis
26.5. Market Attractiveness Analysis By Iran
27. Market Structure Analysis
27.1. Market Analysis by Tier of Companies
27.2. Market Share Analysis of Top Players
27.3. Market Presence Analysis
27.3.1. Regional Footprint Analysis
27.3.2. Product Footprint Analysis
27.3.3. Channel Footprint Analysis
28. Competition Analysis
28.1. Competition Dashboard
28.2. Competition Benchmarking
28.3. Competition Deep Dive
28.3.1. AbbVie Inc.
28.3.1.1. Overview
28.3.1.2. Product Portfolio
28.3.1.3. Key Financials
28.3.1.4. SWOT Analysis
28.3.1.5. Sales Footprint
28.3.1.6. Strategy Overview
28.3.1.7. Key Developments
28.3.1.7.1. Marketing Strategies
28.3.1.7.2. Product Strategies
28.3.1.7.3. Channel Strategies
28.3.2. Eisai Co Ltd
28.3.2.1. Overview
28.3.2.2. Product Portfolio
28.3.2.3. Key Financials
28.3.2.4. SWOT Analysis
28.3.2.5. Sales Footprint
28.3.2.6. Strategy Overview
28.3.2.7. Key Developments
28.3.2.7.1. Marketing Strategies
28.3.2.7.2. Product Strategies
28.3.2.7.3. Channel Strategies
28.3.3. Zydus Cadila
28.3.3.1. Overview
28.3.3.2. Product Portfolio
28.3.3.3. Key Financials
28.3.3.4. SWOT Analysis
28.3.3.5. Sales Footprint
28.3.3.6. Strategy Overview
28.3.3.7. Key Developments
28.3.3.7.1. Marketing Strategies
28.3.3.7.2. Product Strategies
28.3.3.7.3. Channel Strategies
28.3.4. AMillioneal Pharmaceuticals, Inc.
28.3.4.1. Overview
28.3.4.2. Product Portfolio
28.3.4.3. Key Financials
28.3.4.4. SWOT Analysis
28.3.4.5. Sales Footprint
28.3.4.6. Strategy Overview
28.3.4.7. Key Developments
28.3.4.7.1. Marketing Strategies
28.3.4.7.2. Product Strategies
28.3.4.7.3. Channel Strategies
28.3.5. Pfizer Inc.
28.3.5.1. Overview
28.3.5.2. Product Portfolio
28.3.5.3. Key Financials
28.3.5.4. SWOT Analysis
28.3.5.5. Sales Footprint
28.3.5.6. Strategy Overview
28.3.5.7. Key Developments
28.3.5.7.1. Marketing Strategies
28.3.5.7.2. Product Strategies
28.3.5.7.3. Channel Strategies
28.3.6. Amgen Inc.
28.3.6.1. Overview
28.3.6.2. Product Portfolio
28.3.6.3. Key Financials
28.3.6.4. SWOT Analysis
28.3.6.5. Sales Footprint
28.3.6.6. Strategy Overview
28.3.6.7. Key Developments
28.3.6.7.1. Marketing Strategies
28.3.6.7.2. Product Strategies
28.3.6.7.3. Channel Strategies
28.3.7. Celltrion, Inc.
28.3.7.1. Overview
28.3.7.2. Product Portfolio
28.3.7.3. Key Financials
28.3.7.4. SWOT Analysis
28.3.7.5. Sales Footprint
28.3.7.6. Strategy Overview
28.3.7.7. Key Developments
28.3.7.7.1. Marketing Strategies
28.3.7.7.2. Product Strategies
28.3.7.7.3. Channel Strategies
28.3.8. Coherus BioSciences, Inc.
28.3.8.1. Overview
28.3.8.2. Product Portfolio
28.3.8.3. Key Financials
28.3.8.4. SWOT Analysis
28.3.8.5. Sales Footprint
28.3.8.6. Strategy Overview
28.3.8.7. Key Developments
28.3.8.7.1. Marketing Strategies
28.3.8.7.2. Product Strategies
28.3.8.7.3. Channel Strategies
28.3.9. F. Hoffmann–La Roche Ltd
28.3.9.1. Overview
28.3.9.2. Product Portfolio
28.3.9.3. Key Financials
28.3.9.4. SWOT Analysis
28.3.9.5. Sales Footprint
28.3.9.6. Strategy Overview
28.3.9.7. Key Developments
28.3.9.7.1. Marketing Strategies
28.3.9.7.2. Product Strategies
28.3.9.7.3. Channel Strategies
28.3.10. Alexion
28.3.10.1. Overview
28.3.10.2. Product Portfolio
28.3.10.3. Key Financials
28.3.10.4. SWOT Analysis
28.3.10.5. Sales Footprint
28.3.10.6. Strategy Overview
28.3.10.7. Key Developments
28.3.10.7.1. Marketing Strategies
28.3.10.7.2. Product Strategies
28.3.10.7.3. Channel Strategies
28.3.11. Janssen Biotech, Inc.
28.3.11.1. Overview
28.3.11.2. Product Portfolio
28.3.11.3. Key Financials
28.3.11.4. SWOT Analysis
28.3.11.5. Sales Footprint
28.3.11.6. Strategy Overview
28.3.11.7. Key Developments
28.3.11.7.1. Marketing Strategies
28.3.11.7.2. Product Strategies
28.3.11.7.3. Channel Strategies
28.3.12. Hikima Pharmaceuticals plc.
28.3.12.1. Overview
28.3.12.2. Product Portfolio
28.3.12.3. Key Financials
28.3.12.4. SWOT Analysis
28.3.12.5. Sales Footprint
28.3.12.6. Strategy Overview
28.3.12.7. Key Developments
28.3.12.7.1. Marketing Strategies
28.3.12.7.2. Product Strategies
28.3.12.7.3. Channel Strategies
29. Assumptions and Acronyms Used
30. Research Methodology
Explore Healthcare Insights
View Reports
MEA Biologics and Biosimilar Market
